Benchmark analyst Robert Wasserman noted that pharmaceutical non-profit group Harm Reduction Therapeutics announced that their application for an over-the-counter version of anti-opioid overdose nasal naloxone spray has been accepted by the FDA with a PDUFA date of April 28, which is about a month after Emergent BioSolutions’ OTC version’s PDUFA date of March 29. If approved, HRT plans to sell its Rivive product for $18 per dose while giving away one tenth of its production altogether, while Emergent’s NARCAN spray recently sold for a cash price of $100, Wasserman tells investors. The analyst, who said nasal naloxone products are expected to account for up to 35% of Emergent’s revenues this year, continues to rate shares at Hold due to negative quarterly earnings comparisons expected in the near-term.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EBS:
- Emergent BioSolutions: FDA accepts for review sNDA for Narcan Nasal Spray
- Emergent BioSolutions announces FDA acceptance of Narcan sNDA for review
- Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
- Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
- Biotech Alert: Searches spiking for these stocks today
